Research Article

The Efficacy and Safety of Mizoribine versus Mycophenolate Mofetil for the Treatment of Renal Transplantation: A Systematic Review and Meta-Analysis

Jie Chen,1 Hua Liu,2 Wenjun Yin,1 Zhengguang Xu,1 Zekai Chen,1 and Wingkeung Yiu1

1Urinary Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China
2Urinary Surgery, Southern Hospital of Southern Medical University, Guangzhou, China

Correspondence should be addressed to Wingkeung Yiu; 18404112@masu.edu.cn

Received 5 May 2022; Revised 22 June 2022; Accepted 25 June 2022; Published 22 July 2022

Copyright © 2022 Jie Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Mizoribine (MZR) is widely used in Asia due to its high safety and low cost, and comparative studies of its safety and efficacy with the first-line drug mycophenolate mofetil (MMF) have been carried out. This paper aimed to compare the efficacy and safety of MZR and MMF in immunosuppressive therapy of renal transplantation by meta-analysis. Methods. We searched randomized controlled trials (RCTs) comparing MZR versus MMF for renal transplantation in PubMed, Excerpta Medica Database (EMBASE), Cochrane Library, Web of Science, WanFang Database, China National Knowledge Infrastructure (CNKI), and Chinese Biomedical Database (CBM). Articles were assessed for their risk of bias using the Cochrane Collaboration. Forest plots and funnel plots were also performed on the included articles. Results. A total of twelve studies with 1103 patients were selected in the analysis. No significant difference were observed between the MZR group and the MMF group for the rate of acute rejection (RR = 1.50, 95% CI 1.11 to 2.01, P = 0.008), patient survival (RR = 1.01, 95% CI 0.99 to 1.03, P = 0.56), graft survival (RR = 1.02, 95% CI 1.00 to 1.04, P = 0.12), leucopenia (RR = 0.69, 95% CI 0.44 to 1.10, P = 0.12), and liver damage (RR = 0.72, 95% CI 0.46 to 1.13, P = 0.15). The MZR group was associated with a lower risk of gastrointestinal disorder (RR = 0.28, 95% CI 0.13 to 0.62, P = 0.002) and cytomegalovirus infection (RR = 0.59, 95% CI 0.42 to 0.84, P = 0.003) but had a higher risk of hyperuricemia (RR 1.79, 95% CI 1.17 to 2.75, P = 0.007). No significant publication bias was observed among included studies. Discussion. MZR is similar to MMF in efficacy, and in terms of safety, MZR has a lower risk of gastrointestinal disorder and cytomegalovirus infection but a higher risk of hyperuricemia.

1. Introduction

Renal transplantation has been widely carried out all over the world, which would be the most mature solid organ transplantation technology at present [1]. With the renewal and application of new immunosuppressive drugs, the maturity of matching technology and renal transplantation technology, the incidence of short-term rejection after transplantation has been significantly reduced, and the incidence of adverse prognostic events caused by rejection has been reduced [2, 3]. When the shortage of organs cannot be overcome at present, how to ensure the longest functional survival of available organs is one of the hot issues discussed in clinical work.

The triple immunosuppressive regimen of calcineurin inhibitors (CNIs) combined with antiproliferative drugs and hormones has been widely used to prevent and treat rejection after renal transplantation [4, 5]. The application of CNI is the basis for the success of renal transplantation, but CNIs can cause many adverse reactions, which limit their long-term application in the clinical practice of organ transplantation. The combined use of antiproliferative drugs can reduce the dosage of CNIs, then reduce its renal injury, and will not increase the incidence of rejection [6]. Antiproliferative immunosuppressants mainly include mizoribine (MZR), azathioprine (AZA), and mycophenolate mofetil (MMF). AZA is rarely used in recipients after renal transplantation because of its severe hepatotoxicity and bone
2. Methods

2.1. Literature Search Strategy. We performed a systematic search for relevant literature from the following databases up to April 2022 in PubMed, Excerpta Medica Database (EMBASE), Web of Science, Cochrane Library, WanFang Database, Chinese BioMedical Database (CBM), and China National Knowledge Infrastructure (CNKI). Search terms were constructed by using Boolean operator “AND” or “OR” of the following keywords: (1) mizoribine; (2) mycophenolate mofetil; (3) renal transplantation; and (4) kidney transplantation. No language restrictions were applied on searches. We attempted to identify additional studies by reviewing the reference lists to identify any studies that our search strategy may have missed.

2.2. Study Selection. We considered studies to be eligible for inclusion if they met the following criteria:

(1) Population: patients after renal transplantation
(2) Study design: randomized controlled trials (RCTs)
(3) Intervention and control: researches comparing patients receive MZR and MMF
(4) Outcomes: efficacy outcomes, such as acute rejection and patient survival; safety outcomes, such as leukopenia, cytomegalovirus infection, and hyperuricemia
(5) Language: the publication was available in either English or Chinese

2.3. Data Extraction and Quality Assessment. Two authors (JChen and HLiu) collected data independently, and any different opinions between the two authors were resolved by discussions with the third author for a consensus decision. The data extracted from each article included basic information (study design, author’s name and country, publication year, duration, and time of follow-up), and patient’s demographic details (sample size, age, sex, and drug dosage). We used the Cochrane Risk of Bias Tool for methodological quality as all the included studies were RCTs.

2.4. Statistical Analysis. Meta-analysis was performed using Review Manager (version 5.4, Nordic Cochrane Centre) and STATA (version 14.0, STATA Corporation). We expressed dichotomous outcome data as risk ratios (RRs) with 95% confidence intervals (CIs) and continuous outcome data as mean differences (MDs) with 95% CIs. Heterogeneity of the data was assessed using I² values. If I² was <50%, we used a fixed-effect model to pool the data; otherwise, we used a random-effect model for meta-analysis. The funnel plot and Egger's test was conducted to assess the potential publication bias.

3. Results

3.1. Search Process. A total of 1038 potentially eligible studies were identified. Of the identified articles, 125 were duplicates and removed, 789 articles were excluded after reading the titles and abstracts. After the full-texts screening, 12 RCTs, including 1103 patients, met the inclusion criteria and were then included in this meta-analysis [15–26]. The details of our literature search and selection process are shown in Figure 1.

3.2. Characteristics of the Included Studies. The baseline characteristics of the selected studies are presented in Table 1. In total, 1103 patients were included. All 12 articles were published from 2003 to 2020, six came from China, five came from Japan, and one came from Korea. Four articles were published in Chinese and the others were in English. The time of follow-up ranged from 6 to 50 months.

3.3. Results of Quality Assessment. Overall, all the trials were deemed to be at unclear risk of allocation concealment (selection bias) and blinding of participants and personnel (performance bias), five studies were deemed to be at unclear risk of random sequence generation (selection bias), and all studies did not have high risk of bias (Figure 2(a)). A summary of all kind of bias in each study is shown in Figure 2(b).
3.4. Meta-Analysis of Efficacy Outcomes

3.4.1. Acute Rejection. Ten studies comprising 983 patients provided information regarding acute rejection. The MZF group demonstrated significantly lower rate of acute rejection (RR = 1.50, 95% CI 1.11 to 2.01, \( P = 0.008, I^2 = 0\% \), fixed-effect model) compared with the MMF group (Figure 3).

3.4.2. Patient Survival. Patient survival was reported in nine studies involving 743 patients. Pooled results failed to show statistically significant differences for patient survival between the MZR and MFF group (RR = 1.01, 95% CI 0.99 to 1.03, \( P = 0.56, I^2 = 0\% \), fixed-effect model) (Figure 4).

3.4.3. Graft Survival. In the evaluation of difference of graft survival between the MZR group and MMF group, ten articles involved 804 patients were included. Similarly, no statistical significance of graft survival incidence was found between the two groups (RR = 1.02, 95% CI 1.00 to 1.04, \( P = 0.12, I^2 = 0\% \), fixed-effect model) (Figure 5).

3.5. Meta-Analysis of Safety Outcomes

3.5.1. Leukopenia. A total of 762 patients enrolled in nine studies were compared on the frequency of leukopenia. There was no significant difference in the incidence of leukopenia for those patients who received MZR compared with MMF (RR = 0.69, 95% CI 0.44 to 1.10, \( P = 0.12, I^2 = 36\% \), fixed-effect model) (Figure 6).

3.5.2. Liver Damage. Two studies contributed to analysis of liver damage. No significant difference in incidence of liver damage was detected in patients who were treated with MZR compared with MMF (RR = 0.72, 95% CI 0.46 to 1.13, \( P = 0.15, I^2 = 0\% \), fixed-effect model) (Figure 7).

3.5.3. Gastrointestinal Disorder. Ten trials evaluated gastrointestinal disorder between the MZR group and MMF group. Significant heterogeneity was found (\( P = 0.01, I^2 = 56\% \)). Consequently, the random-effect model was applied. The MZR group was markedly beneficial in improving gastrointestinal disorder compared with the MMF group (RR = 0.28, 95% CI 0.13 to 0.62, \( P = 0.002 \)) (Figure 8).

3.5.4. Cytomegalovirus Infection. With regard to cytomegalovirus infection, seven trails involving 532 patients were selected. The pooled analysis showed that the MZF group had a significantly lower rate of cytomegalovirus infection than the MMF group (RR = 0.59, 95% CI 0.42 to 0.84, \( P = 0.003, I^2 = 38\% \), fixed-effect model) (Figure 9).

3.5.5. Hyperuricemia. All the included studies had data available for analysis of hyperuricemia. The MZR group showed a significantly higher incidence of hyperuricemia compared with the MMF group (RR = 1.79, 95% CI 1.17 to 2.75, \( P = 0.007 \), random-effect model). There is significant heterogeneity between the included studies (\( P = 0.002, I^2 = 63\% \)) (Figure 10).
| Study     | Country | Language | Study design | No. of patients | Gender (M/F) | Age | Dosages | Follow-up | Duration |
|-----------|---------|----------|--------------|-----------------|--------------|-----|---------|-----------|----------|
| Ming 2003 | China   | Chinese  | RCT          | 20/20           | -/-          | -/- | 100 mg/d | 1.5 g/d   | 6 months | 2001     |
| Yan 2008  | China   | Chinese  | RCT          | 100/100         | -/-          | -/- | 50–100 mg/d | 1–1.5 g/d | 12 months | 2002     |
| Han 2010  | China   | Chinese  | RCT          | 35/35           | 23/12        | 41.6 ± 10.5 | 42.1 ± 10.6 | 150–200 mg/d | 1–1.5 g/d | 12 months | September 2004 to November 2005 |
| Chen 2012 | China   | Chinese  | RCT          | 33/28           | 21/12        | 40.2 ± 11.5 | 38.6 ± 9.9  | 150–200 mg/d | 1–1.5 g/d | 6 months | January 2010 to October 2010 |
| Ju 2013   | Korea   | English  | RCT          | 110/109         | 70/40        | 44.6 ± 10.9 | 44.2 ± 11.1 | 100–300 mg/d | 1–2 g/d   | 6 months | July 2008 to January 2011 |
| Takahara 2013 | Japan | English  | RCT          | 16/19           | 9/7          | 36.1 ± 7.2  | 39.7 ± 11.3 | 350–600 mg/d | 1–2 g/d   | 12 months | July 2005 to June 2007 |
| Yoshimura 2013 | Japan | English  | RCT          | 40/38           | 23/17        | 41 ± 13     | 35 ± 14     | 6 mg/kg/d   | 25 mg/kg/d | 24 months | October 2004 to July 2007 |
| Yoshimura 2014 | Japan | English  | RCT          | 12/12           | 7/5          | 50 ± 10     | 50 ± 13     | 6 mg/kg/d   | 1 g/d     | 36 months | October 2007 to April 2010 |
| Ishida 2016 | Japan   | English  | RCT          | 41/42           | 26/15        | 41.7 ± 14.4 | 42.3 ± 12.5 | 700 mg/d    | 2 g/d     | 12 months | October 2008 to December 2013 |
| Ushigome 2016 | Japan | English  | RCT          | 90/81           | 56/34        | 42.5 ± 13.5 | 39.2 ± 13.1 | 6 mg/kg/d   | 30 mg/kg/d | 24 months | February 2006 to June 2008 |
| Shi 2019  | China   | English  | RCT          | 22/20           | 20/2         | 30.4 ± 7.7  | 29.4 ± 8.4  | 3 mg/kg/d   | 1.5 g/d   | 36 months | January 2012 to August 2014 |
| Huang 2020 | China   | English  | RCT          | 40/40           | 21/19        | 27.5 (3–57) | 28.5 (6–54) | 3 mg/kg/d   | 15 mg/kg/d | 50.7 months | March 2014 to March 2017 |

MZR, mizoribine; MMF, mycophenolate mofetil.
Blinding of participants and personnel (performance bias)
Allocation concealment (selection bias)
Blinding of outcome assessment (detection bias)
Selective reporting (reporting bias)
Other bias

Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias

Figure 2: Quality assessment of included studies. (a) Risk of bias summary of each included study; (b) Overall risk of bias of included studies.

| Study or Subgroup | MZR Events | Total | MMF Events | Total | Weight (%) | Risk Ratio M-H, Fixed, 95% CI | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|------------|-------|------------|-------|------------|-------------------------------|-------------------------------|
| Chen 2012         | 5          | 33    | 3          | 28    | 5.3        | 1.41 [0.37, 5.40]             |                               |
| Han 2010          | 6          | 35    | 4          | 35    | 6.5        | 1.50 [0.46, 4.86]             |                               |
| Ishida 2016       | 7          | 41    | 8          | 42    | 12.8       | 0.90 [0.36, 2.25]             |                               |
| Ju 2013           | 25         | 110   | 10         | 109   | 16.3       | 2.48 [1.25, 4.91]             |                               |
| Shi 2019          | 4          | 22    | 2          | 20    | 3.4        | 1.82 [0.37, 8.88]             |                               |
| Takahara 2013     | 4          | 16    | 4          | 19    | 5.9        | 1.19 [0.35, 4.01]             |                               |
| Ushigome 2016     | 19         | 90    | 13         | 81    | 22.1       | 1.32 [0.69, 2.49]             |                               |
| Yan 2008          | 11         | 100   | 9          | 100   | 14.6       | 1.22 [0.53, 2.82]             |                               |
| Yoshimura 2013    | 10         | 40    | 6          | 38    | 10.0       | 1.58 [0.64, 3.93]             |                               |
| Yoshimura 2014    | 3          | 12    | 2          | 12    | 3.2        | 1.50 [0.30, 7.43]             |                               |
| Total (95% CI)    | 499        | 484   | 100.0      | 1.50  [1.11, 2.01] |                               |
| Total events      | 94         | 61    |            |       |            |                               |                               |

Heterogeneity: $\chi^2 = 3.88, df = 9 (P = 0.92); I^2 = 0$
Test for overall effect: $Z = 2.66 (P = 0.008)$

Figure 3: Forest plot: MZR versus MMF for acute rejection. MZR, mizoribine; MMF, mycophenolate mofetil; CI, confidence interval; df, degrees of freedom.
3.6. Publication Bias. The publication bias test was conducted when the included studies were at least $\geq 10$ by using the funnel plot and Egger’s test, so we performed the tests on the outcomes of acute rejection, graft survival, gastrointestinal disorder, and hyperuricemia. The funnel plots for acute rejection and graft survival were visually symmetrical, and Egger’s test also showed no significant publishing bias (acute rejection, $P = 0.764$; graft survival, $P = 0.618$). Even though the shape of funnel plots for gastrointestinal disorder and hyperuricemia showed some evidence of asymmetry, the $P$ value of Egger’s test was nonsignificant (gastrointestinal disorder, $P = 0.185$; hyperuricemia, $P = 0.327$) (Figure 11).

4. Discussion

At present, renal transplantation mainly relies on the classic triple immunosuppressive therapy of calmodulin phosphatase inhibitor, MMF, and hormone to control acute rejection. However, AZA has significant hepatotoxicity and hematotoxicity, MMF is often accompanied by opportunistic virus infection that is difficult to control, and it is expensive [27, 28]. Therefore, the transplantation urgently needs new drugs with a good curative effect, good safety, and moderate price so as to provide more choices for clinicians.

As an antimetabolic immunosuppressant, MZR has mild adverse reactions. According to early studies, its
antirejection effect is also weaker than MMF, so it is not
widely used in countries other than Japan. International
reports on the application of MZR in the field of renal
transplantation also come from Japan [29, 30]. It was de-
veloped as an antifungal drug in the early stage and later
found to have an anticell proliferation effect. In the twenty-
first century, it is usually used as an alternative drug for
MMF after renal transplantation in Asia, especially in China,
Japan, South Korea, and other countries [16, 19, 23]. The
main reasons for choosing MZR to replace MMF are as
follows:

(1) MZR has an active structure similar to the antiviral
drug ribavirin, so it has a certain inhibitory effect on
a variety of viruses, while Japanese scholars believe
that MZR may also have a certain inhibitory effect on
BK virus (BKV) in the diagnosis and treatment of
patients with BKV urine after renal transplantation.
(2) Early Brennan and other scholars have verified that
MMF immunosuppressive regimen is one of the risk
factors of BKV reactivation.
(3) The immunosuppressive effect of low-dose (1-3 mg/
kg/d) MZR after renal transplantation is weaker than
that of MMF, while high-dose (5-6 mg/kg/d) MZR is
considered to provide the same immunosuppressive
intensity as MMF.

Therefore, in theory, when MMF is converted to MZR, it
can not only rely on its anti-BKV activity but also increase
the self-specific immune effect against BKV due to the
decrease of immunosuppression so as to comprehensively
inhibit the replication of BKV [31–33].
In our paper, the meta-analysis was used to evaluate the efficacy and safety of MZR and MMF in renal transplant recipients. The results showed that there was no significant difference in the incidence of acute rejection, patient survival, and graft survival rate between MZR and MMF groups, which were consistent with the results of Xing et al. [34]. In terms of safety, there was no significant difference in the incidence of leucopenia and liver damage between the MZR group and MMF group, but the incidence of gastrointestinal disorder and cytomegalovirus infection in the MZR group was lower than that in the MMF group. Except that the difference in the incidence of cytomegalovirus infection was inconsistent with the research results of Li et al. [35], other safety results were consistent, and it may be related to the fact that Li’s study only included four literatures for cytomegalovirus infection, while we included seven, and the result was more reliable.

The good tolerance of MZR in the gastrointestinal tract has obvious advantages. It can be used as an alternative treatment for diarrhea in renal transplant recipients so as to improve the compliance of renal transplant recipients. Infection is one of the main complications after renal transplantation, and it is also an important factor affecting the survival rate of recipients and transplanted kidneys, especially cytomegalovirus infection [36]. Mild cases are asymptomatic viremia, and severe cases are often life-threatening. MZR has been proved to inhibit cytomegalovirus in vitro in a dose-response relationship [37]. Its antiviral mechanism may be similar to its chemical structure and broad-spectrum antiviral drug ribavirin. MZR can reduce the incidence of infection without increasing the risk of

| Study or Subgroup | MZR Events | MMF Events | Weight (%) | Risk Ratio M-H, Random, 95% CI | Risk Ratio M-H, Random, 95% CI |
|-------------------|------------|------------|------------|--------------------------------|--------------------------------|
| Chen 2012         | 0          | 33         | 3          | 4                              | 28                              | 5.6                          | 0.09 [0.01, 1.69] |
| Han 2010          | 0          | 35         | 1          | 35                              | 4.8                            | 0.33 [0.01, 7.91] |
| Ju 2013           | 38         | 110        | 39         | 109                             | 22.2                           | 0.97 [0.67, 1.38] |
| Ming 2003         | 2          | 20         | 8          | 20                              | 13.2                           | 0.25 [0.06, 1.03] |
| Shi 2019          | 0          | 22         | 7          | 20                              | 5.8                            | 0.06 [0.00, 1.00] |
| Takahara 2013     | 0          | 16         | 2          | 19                              | 5.3                            | 0.24 [0.01, 4.57] |
| Ushigome 2016     | 1          | 90         | 7          | 81                              | 8.8                            | 0.13 [0.02, 1.02] |
| Yan 2008          | 4          | 100        | 12         | 100                             | 16.0                           | 0.33 [0.11, 1.00] |
| Yoshimura 2013    | 2          | 40         | 9          | 38                              | 12.8                           | 0.21 [0.05, 0.91] |
| Yoshimura 2014    | 0          | 12         | 2          | 12                              | 5.4                            | 0.20 [0.01, 3.77] |
| **Total (95% CI)** | 478        | 462        | **100.0**  | **47**                          | **91**                         | **0.28 [0.13, 0.62]** |

Test for overall effect: Z = 3.16 (P = 0.002)

Figure 8: Forest plot: MZR versus MMF for gastrointestinal disorder. MZR, mizoribine; MMF, mycophenolate mofetil; CI, confidence interval; df, degrees of freedom.

| Study or Subgroup | MZR Events | MMF Events | Weight (%) | Risk Ratio M-H, Fixed, 95% CI | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|------------|------------|------------|--------------------------------|--------------------------------|
| Chen 2012         | 0          | 33         | 3          | 28                              | 6.3                            | 0.12 [0.01, 2.26] |
| Huang 2020        | 19         | 40         | 22         | 40                              | 36.8                           | 0.86 [0.56, 1.33] |
| Ishida 2016       | 6          | 41         | 9          | 42                              | 14.9                           | 0.68 [0.27, 1.75] |
| Takahara 2013     | 2          | 16         | 7          | 19                              | 10.7                           | 0.34 [0.08, 1.41] |
| Ushigome 2016     | 0          | 90         | 10         | 81                              | 18.5                           | 0.04 [0.00, 0.72] |
| Yoshimura 2013    | 7          | 40         | 6          | 38                              | 10.3                           | 1.11 [0.41, 3.00] |
| Yoshimura 2014    | 0          | 12         | 1          | 12                              | 2.5                            | 0.33 [0.01, 7.45] |
| **Total (95% CI)** | 272        | 260        | **100.0**  | **58**                          | **0.59 [0.42, 0.84]** |

Test for overall effect: Z = 2.93 (P = 0.003)

Figure 9: Forest plot: MZR versus MMF for cytomegalovirus infection. MZR, mizoribine; MMF, mycophenolate mofetil; CI, confidence interval; df, degrees of freedom.
### Table 1: Study or Subgroup Events Total Events Total Weight (%)

| Study or Subgroup | MZR Events | MZR Total | MMF Events | MMF Total | Weight (%) | Risk Ratio M-H, Random, 95% CI | Risk Ratio M-H, Random, 95% CI |
|-------------------|------------|-----------|------------|-----------|------------|---------------------------------|---------------------------------|
| Chen 2012         | 3          | 33        | 2          | 28        | 4.5        | 1.27 [0.23, 7.09]               |                                 |
| Han 2010          | 5          | 35        | 1          | 35        | 3.3        | 5.00 [0.62, 40.64]              |                                 |
| Huang 2020        | 12         | 40        | 4          | 40        | 8.3        | 3.00 [1.06, 8.52]               |                                 |
| Ishida 2016       | 7          | 41        | 3          | 42        | 6.6        | 2.39 [0.66, 8.62]               |                                 |
| Ju 2013           | 27         | 110       | 37         | 109       | 14.3       | 0.72 [0.48, 1.10]               |                                 |
| Ming 2003         | 4          | 20        | 2          | 20        | 5.1        | 2.00 [0.41, 9.71]               |                                 |
| Shi 2019          | 11         | 20        | 8          | 18        | 11.9       | 1.24 [0.65, 2.37]               |                                 |
| Takahara 2013     | 6          | 16        | 4          | 19        | 8.1        | 1.78 [0.61, 5.23]               |                                 |
| Ushigome 2016     | 52         | 90        | 23         | 81        | 14.6       | 2.03 [1.38, 3.00]               |                                 |
| Yan 2008          | 25         | 100       | 6          | 100       | 10.0       | 4.17 [1.79, 9.72]               |                                 |
| Yoshimura 2013    | 10         | 40        | 1          | 38        | 3.6        | 9.50 [1.28, 70.70]              |                                 |
| Yoshimura 2014    | 5          | 12        | 6          | 12        | 9.7        | 0.83 [0.35, 2.00]               |                                 |
| Total (95% CI)    | 557        | 542       | 100.0      | 100.0     | 1.79 [1.17, 2.75]               |                                 |

Heterogeneity: Tau² = 0.29; Chi² = 29.50, df = 11 (P = 0.002); I² = 63%
Test for overall effect: Z = 2.68 (P = 0.007)

**Figure 10:** Forest plot: MZR versus MMF for hyperuricemia. MZR, mizoribine; MMF, mycophenolate mofetil; CI, confidence interval; df, degrees of freedom.

![Forest plot](image1)

**Figure 11:** Funnel plot for publication bias in this meta-analysis (a) Acute rejection; (b) Graft survival; (c) Gastrointestinal disorder; (d) Hyperuricemia.

![Funnel plot](image2)
rejection. It can effectively help renal transplant recipients through the high-risk infection period especially for high-risk infection recipients such as perioperative lung infection, retransplantation, and the use of polyclonal antibodies.

Hyperuricemia is a common adverse reaction of MZR. It mainly leads to the increase of guanine and xanthine nucleoside by inhibiting the activity of hypoxanthine nucleoside phosphate dehydrogenase so as to increase xanthine and uric acid, which is positively correlated with the drug dose. Therefore, the blood uric acid level of the recipient should be monitored during the administration of MZR [38]. If necessary, the dose of MZR can be reduced or uric acid lowering drugs such as allopurinol and benzbromarone can be added to maintain the normal blood uric acid level.

There were still some limitations in this study: (1) Although 12 literatures were included, the sample size was only 1103, which was still small; (2) the follow-up time ranged from 6 to 50 months due to the small number of literatures, and it was impossible to make subgroup analysis of short-term and long-term effects; (3) the research population was limited to China, Japan, and South Korea, and there was a lack of research on other regions; and (4) the dosage of each study and the type of transplanted renal were different, which may affect the accuracy of the final conclusion.

### 5. Conclusions

In conclusion, there is no significant difference in the efficacy of rejection between MZR and MMF in the prognosis of renal transplantation. In terms of safety, there is also no significant difference between the two groups in the incidence of leucopenia and liver damage; compared with the MMF group, the incidence of gastrointestinal disorder and cytomegalovirus infection in the MZR group was lower, but the incidence of hyperuricemia was higher. Limited to the design and quality of the included study, more large samples, more regions, and longer follow-up RCTs are needed to verify the conclusion.

### Data Availability

The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.

### Conflicts of Interest

All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare.

### Authors’ Contributions

Jie Chen and Hua Liu contributed equally to this work.

### References

[1] P. J. Morris, R. J. Johnson, S. V. Fuggle, M. A. Belger, and J. D. Briggs, "Analysis of factors that affect outcome of primary cadaveric renal transplantation in the UK," *Lancet (North American Edition)*, vol. 354, no. 9185, pp. 1147–1152, 2019.

[2] R. Boissier, V. Hevia, H. M. Bruins, K. Budde, A. Figueiredo, and J. Olsburgh, "The risk of tumour recurrence in patients undergoing renal transplantation for end-stage renal disease after previous treatment for a urological cancer: a systematic Review - ScienceDirect," *European Urology*, vol. 73, no. 1, pp. 94–108, 2018.

[3] J. D. Schold, B. Kaplan, R. J. Howard, A. I. Reed, D. P. Foley, and H. U. Meier-Kriesche, "Are we frozen in time? Analysis of the utilization and efficacy of pulsatile perfusion in renal transplantation," *American Journal of Transplantation*, vol. 5, no. 7, pp. 1681–1688, 2005.

[4] Y. Qin, F. Zhang, B. Shen et al., "Efficacy and safety of enteric-coated mycophenolate sodium in patients with de novo and maintenance renal transplantation," *International Journal of Clinical Practice*, vol. 68, pp. 17–22, 2014.

[5] D. Y. H. Yap and T. M. Chan, "Treatment of lupus nephritis: practical issues in Asian countries," *International Journal of Rheumatic Diseases*, vol. 18, no. 2, pp. 138–145, 2015.

[6] A. Sonoda, K. Wada, K. Mizukami et al., "Deep ulcers associated with mycophenolate mofetil," *Internal Medicine*, vol. 56, no. 21, pp. 2883–2886, 2017.

[7] F. Ljuca, S. Imamovic, D. Mesić et al., "Micophenolat Mofetil versus Azathioprine: effects on renal graft function in early posttransplant period," *Bosnian Journal of Basic Medical Sciences*, vol. 9, no. 2, pp. 156–160, 2009.

[8] S. Cao, G. O. Aboge, M. A. Terkawi et al., "Mycophenolic acid, mycophenolate mofetil, mizoribine, ribavirin, and 7-nitroindole inhibit propagation of babesia parasites by targeting inosine 5’-Monophosphate dehydrogenase," *The Journal of Parasitology*, vol. 100, no. 4, pp. 522–526, 2014.

[9] J. Sobiak, M. G. Yda, M. Malec, and M. Chrzanowska, "Pharmacokinetics of mycophenolate mofetil metabolites in older patients on the seventh day after renal transplantation in article in press," *Transplantation Proceedings*, vol. 53, pp. 358–365, 2021.

[10] K. Akioka, K. Masuda, S. Harada et al., "Acute renal failure caused by hyperuremic acidemia in ABO-incompatible kidney transplant maintained with cyclosporine and high-dose mizoribine: a case report," *Transplantation Proceedings*, vol. 45, no. 7, pp. 2815–2818, 2013.

[11] Y. Shi, H. Liu, X. G. Chen, and Z. Y. Shen, “Comparison of mizoribine and mycophenolate mofetil with a tacrolimus-based immunosuppressive regimen in living-donor kidney transplantation recipients: a retrospective study in China,” *Transplantation Proceedings*, vol. 49, no. 1, pp. 26–31, 2017.

[12] A. Boyd, A. Brown, J. Patel et al., “Basiliximab with delayed tacrolimus improves short-term renal outcomes post-liver transplantation—a real-world experience,” *Transplantation Proceedings*, vol. 53, no. 5, pp. 1541–1547, 2021.

[13] K. Sugimoto, N. Sakata, S. Fujita et al., “Cure of relapsing polychondritis by an allogeneic marrow graft for chronic myelogenous leukemia,” *Pediatric Nephrology*, vol. 28, no. 6, pp. 975–978, 2013.

[14] S. Ashimine, Y. Watarai, T. Yamamoto et al., “Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation,” *Kidney International*, vol. 85, no. 2, pp. 425–430, 2014.

[15] A. Ming, M. Lin, M. Zhao, L. Yue, M. Li, and L. Fan, “Application of mizoribine in cadaveric renal transplantation,” *Journal of Clinical Urology*, vol. 18, no. 01, pp. 6-7, 2003.
[16] Q. Yan, H. Chen, Y. Jiang, S. Xie, Z. Shen, and W. Kui, "Application of mizoribine in clinical kidney transplantation," Chin J Organ Transplant, vol. 29, no. 1, pp. 14-15, 2008.
[17] S. Han, B. Shen, Y. Fan, and Y. Zhu, "Comparison of two triple immunosuppressive regimens of mizoribine and mycophenolate mofetil in renal transplant patients," Chin J New Drugs, vol. 19, no. 7, pp. 595–598, 2010.
[18] L. Chen, L. Liu, Y. Qian, M. Cai, X. Zhang, and B. Shi, "Efficacy and safety of mizoribine in early postoperative renal transplantations," Chin J Organ Transplant, vol. 33, no. 1, pp. 18–21, 2012.
[19] M. K. Ju, K. H. Huh, K. T. Park et al., "Mizoribine versus mycophenolate mofetil in combination therapy with tacrolimus for de novo kidney transplantation: evaluation of efficacy and safety," Transplantation Proceedings, vol. 45, no. 4, pp. 1481–1486, 2013.
[20] S. Takahara, K. Takahashi, T. Akiyama et al., "Randomized comparative trial of mizoribine versus mycophenolate mofetil in combination with tacrolimus for living donor renal transplantation," Clinical and Experimental Nephrology, vol. 17, no. 6, pp. 899–904, 2013.
[21] N. Yoshimura, H. Ushigome, K. Akioka et al., "The beneficial effect of high-dose mizoribine combined with cyclosporine, basiliximab, and corticosteroids on CMV infection in renal transplant recipients," Clinical and Experimental Nephrology, vol. 17, no. 1, pp. 127–133, 2013.
[22] N. Yoshimura, H. Ushigome, S. Nobori et al., "Usefulness and safety of high-dose mizoribine on ABO-incompatible living related kidney transplantation using anti-cd20 and anti-cd25 antibodies without splenectomy: 3-year results," Transplantation Proceedings, vol. 46, no. 2, pp. 391–394, 2014.
[23] H. Ushigome, K. Uchida, K. Nishimura et al., "Efficacy and safety of high-dose mizoribine combined with cyclosporine, basiliximab, and corticosteroids in renal transplantation: a Japanese multicenter study," Transplantation Proceedings, vol. 48, no. 3, pp. 794–798, 2016.
[24] H. Ishida, S. Takahara, N. Amada et al., "A prospective randomized, comparative trial of high-dose mizoribine versus mycophenolate mofetil in combination with tacrolimus and basiliximab for living donor renal transplant: a multicenter trial," Experimental and Clinical Transplantation :Official Journal of the Middle East Society for Organ Transplantation, vol. 14, no. 5, pp. 518–525, 2016.
[25] Y. Shi, H. Liue, X. G. Chen, and Z. Y. Shen, "Efficacy and safety of mizoribine combined with tacrolimus in living donor kidney transplant recipients: 3-year results by a Chinese single center study," Transplantation Proceedings, vol. 51, no. 5, pp. 1337–1342, 2019.
[26] Y. Huang, M. Han, D. Yang et al., "Comparative study of mizoribine and mycophenolate mofetil combined with a calcineurin inhibitor-based immunosuppressive regimen in patients with alternative donor hematopoietic cell transplantation," Biology of Blood and Marrow Transplantation, vol. 26, no. 9, pp. 1663–1669, 2020.
[27] H. R. Whalen, J. A. Glen, V. Harkins et al., "High intrapatient tacrolimus variability is associated with worse outcomes in renal transplantation using a low-dose tacrolimus immunosuppressive regime," Transplantation, vol. 101, no. 2, pp. 430–436, 2017.
[28] J. Bamoulid, A. Roodenburg, O. Staeck et al., "Clinical outcome of patients with de novo C1q-binding donor-specific HLA antibodies after renal transplantation," Transplantation, vol. 101, no. 9, pp. 2165–2174, 2017.
[29] K. Koshino, H. Ushigome, T. Nakao et al., "Usefulness of follow-up biopsies at one year after ABO-incompatible kidney transplantation," Transplantation Proceedings, vol. 46, no. 2, pp. 385–387, 2014.
[30] N. Ichimaru, K. Yamanaka, T. Kato et al., "Risk factors and incidence for lipid abnormalities in kidney transplant patients," Transplantation Proceedings, vol. 47, no. 3, pp. 672–674, 2015.
[31] L. Ye, F. Xiao, J. Xie et al., "Synergistic renoprotective effects of sesame oil and erythropoietin on ischemic kidney injury after renal transplantation," AMB Express, vol. 10, no. 1, p. 4, 2020.
[32] J. Sobiak and M. Resztak, "A systematic Review of multiple linear regression-based limited sampling strategies for mycophenolic acid area under the concentration–time curve estimation," European Journal of Drug Metabolism and Pharmacokinetics, vol. 46, no. 6, pp. 721–742, 2021.
[33] X. Ding, X. Zhu, Y. Zhang et al., "Influence of serum uric acid levels in response to the conversion from mycophenolate mofetil to mizoribine in kidney transplant recipients," Transplantation Proceedings, vol. 45, no. 1, pp. 190–193, 2013.
[34] S. Xing, J. Yang, X. Zhang, and P. Zhou, "Comparative efficacy and safety of mizoribine with mycophenolate mofetil for Asian renal transplantation—a meta-analysis," Clinical Biochemistry, vol. 47, no. 7-8, pp. 663–669, 2014.
[35] N. Li, S. Tang, Z. F. Zhu, L. Jing-Li, X. Zhang, and D. Pharmacy, "Efficacy and safety of mizoribine and mycophenolate mofetil after renal transplantation: a Meta-analysis," Chinese Journal of Hospital Pharmacy, vol. 38, no. 10, pp. 1102–1109, 2018.
[36] K. Sallam, G. D. Bhumiireddy, V. D. Evuri et al., "Sirolimus adverse event profile in a non-clinical trial cohort of heart transplantation patients," Annals of Transplantation, vol. 26, p. e923536, 2021.
[37] Y. Qian, B. Shi, J. Ao, and H. Yang, "Clinical application of mizoribine in minimizing virus infection risk in renal graft recipients," Chin J Organ Transplant, vol. 27, no. 12, pp. 723-724, 2006.
[38] J. Ao, X. Xiao, H. Zhang, and H. Yang, "The conversion of mizoribine to treat myelosuppression after renal transplantation," Journal of Clinical Urology, vol. 19, no. 7, pp. 435-436, 2004.